Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA334593
Max Phase: Preclinical
Molecular Formula: C13H11ClN4S
Molecular Weight: 290.78
Molecule Type: Small molecule
Associated Items:
ID: ALA334593
Max Phase: Preclinical
Molecular Formula: C13H11ClN4S
Molecular Weight: 290.78
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(Cl)n2nc(SCc3ccccc3)nc2n1
Standard InChI: InChI=1S/C13H11ClN4S/c1-9-7-11(14)18-12(15-9)16-13(17-18)19-8-10-5-3-2-4-6-10/h2-7H,8H2,1H3
Standard InChI Key: JEDIFYONHROFLZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 290.78 | Molecular Weight (Monoisotopic): 290.0393 | AlogP: 3.38 | #Rotatable Bonds: 3 |
Polar Surface Area: 43.08 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.59 | CX LogD: 3.59 |
Aromatic Rings: 3 | Heavy Atoms: 19 | QED Weighted: 0.55 | Np Likeness Score: -2.27 |
1. Novinson T, Springer RH, O'Brien DE, Scholten MB, Miller JP, Robins RK.. (1982) 2-(Alkylthio)-1,2,4-triazolo[1,5-a]pyrimidines as adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitors with potential as new cardiovascular agents., 25 (4): [PMID:6279846] [10.1021/jm00346a017] |
Source(1):